glp1ledger

What Is Zepbound? The Brand, What It Is Approved For, and How Its Label Has Changed Since 2023

Zepbound is Eli Lilly's brand of tirzepatide for weight management and, since December 2024, obstructive sleep apnea in adults with obesity. It is the same molecule as Mounjaro, sold under a different label. What it is, how it works, the four forms it now comes in, what it is not approved for, and every major label change, from FDA's own records on 3 October 2026.

Ronald R · Edited by Caroline S · Published 2026-10-03 · Updated 2026-11-17

Illustration: A small, unbranded white ceramic bowl with a fine, granular substance on a warm wooden surface.
Illustration

Zepbound is Eli Lilly's brand of tirzepatide for weight management. It was approved in November 2023, gained a second indication — obstructive sleep apnea in adults with obesity — in December 2024, and is the same molecule as Lilly's diabetes brand, Mounjaro, sold under a separate approval with a separate label. It is a once-weekly injection, now in four forms. Set against the oldest weight-management GLP-1, daily liraglutide, its label figures are compared on the Saxenda and Zepbound page.

This page covers the brand: what the label says it is for and what it is not, how the molecule works, the forms it comes in and how its label has changed. It is built from the current prescribing information (Eli Lilly, DailyMed version effective 28 August 2026) and FDA's approval records, read on 3 October 2026. What it achieved in its trials is on our tirzepatide review; the molecule itself is described in Peptide Lexicon's tirzepatide entry. How much weight people lost in each SURMOUNT trial is on Zepbound weight-loss results.

What it is approved for

Section 1 of the label lists two indications, and attaches both to eating fewer calories and moving more:

  1. Weight: for adults, losing excess weight and keeping it off over the long term — at an obesity-range BMI, or at an overweight BMI together with at least one illness linked to weight.
  2. Sleep apnea: treatment of moderate or severe obstructive sleep apnea (OSA) in adults who have obesity. The sleep-apnea evidence is on GLP-1s and sleep apnea.

One limit is attached: because Zepbound is tirzepatide, the label advises against stacking it with Mounjaro or any other tirzepatide product, or with a drug from the GLP-1 class.

Three things it is not approved for, each a common assumption:

  • Type 2 diabetes. That is Mounjaro's indication, set out with its forms and label changes on the Mounjaro brand page. People with diabetes were included in a Zepbound weight trial, but treating diabetes is not on Zepbound's label. How the two brands divide — including an age line that runs the opposite way to the semaglutide brands — is on Mounjaro vs Zepbound.
  • Children or adolescents. Both indications are for adults.
  • Heart protection. Zepbound has no cardiovascular indication — see the label history below.

How it works

The label's mechanism section describes tirzepatide as "a GIP receptor and GLP-1 receptor agonist" — one molecule that acts on the receptors for two gut hormones. In the label's words, GLP-1 "is a physiological regulator of appetite and caloric intake", "nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake", and in animal studies tirzepatide "distributes to and activates neurons in brain regions involved in regulation of appetite and food intake". It also delays stomach emptying, which is behind several of its side effects.

Structurally, tirzepatide is a 4,813.53-dalton peptide built on the GIP sequence, with two unusual amino acids (aminoisobutyric acid at positions 2 and 13) and a 20-carbon fatty diacid attached by a linker. That fatty chain "enables albumin binding and prolongs the half-life" to about five days, which is what makes once-weekly injection possible. The two hormones are explained on GIP and GLP-1, and the class as a whole on how GLP-1 works.

The four forms it comes in

Presentation Doses per unit Approved
Single-dose pen 1 (box of 4) With the brand, 8 November 2023
Single-dose vial 1 Added later; sold singly and in packs of 4
Multi-dose vial 4 7 January 2026 (NDA 217806/S-037)
KwikPen 4 20 January 2026 (NDA 217806/S-002)

Label section 16.1; FDA approval letters. Each comes in the same six strengths, one strength per unit. The multi-dose forms carry a preservative, need a needle and syringe or a pen needle, and are discarded 30 days after first use; the device is described on the Zepbound KwikPen page, and storage for every form on GLP-1 pen storage. The forms also differ in price and in which savings routes apply — set out on Zepbound cost.

How the label has changed

Zepbound's approval file (NDA 217806) records each change FDA has approved. The ones that changed what the label says to a reader:

Date Supplement What changed
8 November 2023 Original Approved for chronic weight management
December 2024 S-013 Obstructive sleep apnea indication added (label Recent Major Changes, 12/2024)
25 September 2025 S-031 Section 8.2, Lactation, revised
7 January 2026 S-037 Multi-dose vial added
20 January 2026 S-002 KwikPen added, 797 days after the application
25 February 2026 S-042 Class-wide GI warnings added (intestinal obstruction, severe constipation including faecal impaction); suicidal ideation warning removed at FDA's request
26 August 2026 S-041 SURPASS-CVOT results added to the diabetic-retinopathy warning

Drugs@FDA submission history and FDA approval letters for NDA 217806, read 3 October 2026. Re-read on 17 November 2026: fifteen actions in all, the ones above plus labelling supplements S-020 (7 February 2025) and S-050 (22 April 2026), whose content the extract does not describe, and no action after 26 August 2026.

How often the label text itself has moved. DailyMed holds 22 published versions of Zepbound's label, from 14 November 2023 to 2 September 2026 — eight of them between 17 November 2025 and 2 September 2026. Version 40, published 2 September 2026, was still current on 17 November 2026. A quotation from "the Zepbound label" is only as good as its date.

Two rows deserve a sentence each.

The suicidal-ideation warning came out at FDA's request, not Lilly's. FDA had opened a safety-signal review of suicidal ideation across the GLP-1 class in July 2023. On 13 January 2026 it asked Lilly to remove the information, and the February 2026 approval took out the former section 5.9, "Suicidal Ideation and Behavior", and the words "depression or thoughts of suicide" from the Medication Guide's list of possible side effects. The approval letter records the request and the removal; it does not publish FDA's reasoning. What the evidence on mood shows is on GLP-1s and depression.

The August 2026 heart-trial update is easy to misread. Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT, compared it with dulaglutide in adults with type 2 diabetes and established cardiovascular disease. Its results supported a cardiovascular indication for Mounjaro. On Zepbound's label, FDA's letter says the supplement added the trial's information to the warning on diabetic retinopathy and aligned the patient counselling text — no cardiovascular indication was added. (FDA letter, NDA 217806/S-041.) A Zepbound reader who has heard "tirzepatide cuts heart risk" should know that claim belongs to another label and another population.

The warnings

Its boxed warning rests on rat studies, in which tirzepatide produced thyroid C-cell tumours; whether that happens in people is, in the label's account, still undetermined. That is why anyone who has had medullary thyroid carcinoma or MEN 2, or has it in the family, is excluded. Its other warnings — pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury from dehydration, hypersensitivity, low blood sugar, retinopathy in people with diabetes, aspiration under anaesthesia, and never sharing a KwikPen — and how often each was seen are on Zepbound side effects.

Who makes it, and how people get it

Eli Lilly and Company holds the approval; it has no generic competitor yet, though generic applications were filed in May 2026, and there is no tablet version — Lilly's pill is a different molecule. Zepbound is dispensed at ordinary pharmacies with a prescription and through Lilly's own pharmacy service, LillyDirect. Savings-card terms are on the Zepbound savings card page, and Medicare's temporary route on the Medicare GLP-1 Bridge. How it compares with the nearest rival brand is on Zepbound vs Wegovy, and against the diabetes brand of semaglutide on Zepbound vs Ozempic. Compounded tirzepatide is a different, unapproved product — see compounded tirzepatide vs Zepbound.

This page reports the label and FDA's records. It is not advice on whether Zepbound suits anyone; that decision belongs with a prescriber.

Sources

  • Eli Lilly and Company, ZEPBOUND (tirzepatide) injection, prescribing information and Medication Guide, DailyMed set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 2026-08-28 — Boxed Warning and sections 1, 3, 4, 5, 11, 12.1, 16.1, dailymed.nlm.nih.gov, read 3 October 2026.
  • Eli Lilly and Company, ZEPBOUND prescribing information revised 12/2024 (S-013), Recent Major Changes, accessdata.fda.gov, read 3 October 2026.
  • US Food and Drug Administration, supplement approval letters for NDA 217806: S-002 (20 January 2026), S-031 (25 September 2025), S-037 (7 January 2026), S-041 (26 August 2026, corrected letter), S-042 (25 February 2026), via accessdata.fda.gov, read 3 October 2026.
  • US Food and Drug Administration, Drugs@FDA submission history for NDA 217806 and NDA 215866 (Mounjaro), via open.fda.gov, queried 3 October 2026.

Frequently asked questions

What is Zepbound used for?

Weight loss and its maintenance in adults — those with obesity, or overweight with at least one weight-related illness — and moderate-to-severe obstructive sleep apnea in adults living with obesity. Diabetes treatment is not on its label; Lilly sells the same molecule for that as Mounjaro.

How does Zepbound work?

Zepbound's active ingredient, tirzepatide, activates the receptors for two gut hormones, GIP and GLP-1. The label describes GLP-1 as one of the body's own regulators of appetite and food intake, says GIP may add to the regulation of food intake, and that in animal studies tirzepatide reaches and activates appetite-regulating areas of the brain. It also slows stomach emptying. A fatty-acid chain on the molecule keeps it in the body for about five days, so it is injected weekly.

Who makes Zepbound?

Eli Lilly and Company, of Indianapolis, which holds the US approval (NDA 217806). Lilly also makes Mounjaro (tirzepatide for type 2 diabetes) and Foundayo (orforglipron, a GLP-1 tablet).

Is Zepbound the same as Mounjaro?

Same molecule, same maker, separate approvals. Mounjaro (approved May 2022) is for type 2 diabetes; Zepbound (approved November 2023) is for weight management and sleep apnea. The labels differ in indication, in age range and in which outcome trials they cite, and the prices and insurance rules follow the brand rather than the molecule.

Is Zepbound FDA approved?

Yes. Zepbound was approved on 8 November 2023 and its sleep-apnea indication in December 2024. Compounded tirzepatide, sold by some telehealth companies and pharmacies, is not Zepbound and is not FDA-approved; the difference is set out on our page comparing compounded tirzepatide with Zepbound.

Does Zepbound reduce heart attack risk?

Not according to its label: Zepbound has no cardiovascular indication. Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT, was run in people with type 2 diabetes against another GLP-1 drug, and supports Mounjaro's indication. In August 2026 its results were added to Zepbound's retinopathy warning only.